I am an Assistant Professor at HKU, in the area of liver transplantation oncology and immunology by leveraging multi-omics and bioengineering approaches.
Oncoimmunostics Limited is a start-up biotech company spun off from University of Hong Kong in 2022. The company is established by Chair Professor Nancy Kwan Man, a professional of transplant oncology and immunology in the world. Oncoimmunostics focuses on precise cancer diagnostics and therapeutics. To tackle the problem of high recurrence rate and low drug response rate in liver cancer, we apply 3D bioprinting technology to invent the biomimetic liver cancer microenvironment "liver-in-cube" which can be used for personalized drug screening for choosing the best treatment. The product can also be used for new drugs development and safety assessment in the pharmaceutical industry, and can be widely applied in basic research for tumor microenvironment. This product has a short manufacturing time, high biomimicry, and is superior to current 3D culture and organoid models, replacing the use of animal models. The company has a strong clinical, basic and translational research team, owns world-leading research outputs in the field of tumor immune microenvironment, possesses a comprehensive tissue bank and patients database. Future directions include developing multiple cancer models to promote early diagnosis, treatment, and precise treatment of cancer.
Dr. Liu is a Research Assistant Professor at the University of Hong Kong. His expertise spans the mechanism discovery and novel therapeutics development for graft dysfunction and cancer recurrence in liver transplantation. His research findings have been published in more than 30 journals including Annals of Surgery, Transplantation, Liver Transplantation, and Small. Dr. Liu has received Vanguard Award for Basic Science Research and Young Investigator Awards from International Liver Transplantation Society (ILTS), Mentee-Mentor Awards from The Transplantation Society (TTS), Young Investigator Award from the International Digestive Disease Forum, and the Best Abstract Award from the Congress of Asian Society of Transplantation. He also serves as a member of ILTS Vanguard Committee (2021-2024), Basic and Translational Research Committee (2025-2028), TTS Early Career Member Committee, Scientific Committee of the International LDLT registry, Steering Committee of Transplantation Science Symposium of Asia, and Working Group for the first Consensus and Guideline Meeting on Perihilar Cholangiocarcinoma.